Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss

[1]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[2]  A. Look,et al.  The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells , 2018, Leukemia.

[3]  A. Letai,et al.  Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. , 2017, Cancer discovery.

[4]  Nancy R. Zhang,et al.  Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. , 2017, Cell reports.

[5]  Catherine A. Shang,et al.  Whole-genome landscapes of major melanoma subtypes , 2017, Nature.

[6]  L. Saal,et al.  NF1‐mutated melanoma tumors harbor distinct clinical and biological characteristics , 2017, Molecular oncology.

[7]  A. Strasser,et al.  The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models , 2016, Nature.

[8]  J. McQuade,et al.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.

[9]  R. Young,et al.  A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation , 2016, Science.

[10]  C. Bourque,et al.  Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish , 2016, Nature Communications.

[11]  B. Glaser,et al.  Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells , 2015, Neuroendocrinology.

[12]  Arati Sharma,et al.  Current State of Animal (Mouse) Modeling in Melanoma Research , 2015, Cancer growth and metastasis.

[13]  S. Ariyan,et al.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas , 2015, Nature Genetics.

[14]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[15]  N. Mukherjee,et al.  Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells , 2015, Journal of Investigative Dermatology.

[16]  Q. Zhong.  Faculty Opinions recommendation of Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. , 2015 .

[17]  Eric Legius,et al.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies , 2014, Nature.

[18]  N. Haass,et al.  Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy , 2014, Pigment cell & melanoma research.

[19]  D. Gewirtz,et al.  Cytotoxic Autophagy in Cancer Therapy , 2014, International journal of molecular sciences.

[20]  A. Alavi,et al.  Combined MTOR and autophagy inhibition , 2014, Autophagy.

[21]  O. Maertens,et al.  An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. , 2014, Advances in biological regulation.

[22]  E. Sunami,et al.  Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells , 2014, Journal of Cancer Research and Clinical Oncology.

[23]  K. Ryan,et al.  Autophagy in tumour cell death. , 2013, Seminars in cancer biology.

[24]  J. Lister,et al.  A Conditional Zebrafish MITF Mutation Reveals MITF Levels Are Critical for Melanoma Promotion vs. Regression In Vivo , 2013, The Journal of investigative dermatology.

[25]  R. Tothill,et al.  BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage , 2013, Clinical Cancer Research.

[26]  D. Schadendorf,et al.  A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. , 2013, Cancer discovery.

[27]  K. Flaherty,et al.  Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.

[28]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[29]  Seok-Hyung Kim,et al.  Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development , 2012, Disease Models & Mechanisms.

[30]  H. Spaink,et al.  Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model , 2012, The Journal of pathology.

[31]  K. Leslie,et al.  A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors , 2011, PloS one.

[32]  D. Neuberg,et al.  Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia , 2011, The Journal of experimental medicine.

[33]  J. Blenis,et al.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.

[34]  David A. Orlando,et al.  The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset , 2011, Nature.

[35]  L. Lam,et al.  A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax) , 2010, Molecular Cancer Therapeutics.

[36]  L. Zon,et al.  Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish. , 2009, Zebrafish.

[37]  M. Gottesman,et al.  Influence of melanosome dynamics on melanoma drug sensitivity. , 2009, Journal of the National Cancer Institute.

[38]  Wei Zhou,et al.  In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.

[39]  J. Dixon,et al.  Zebrafish pten genes have overlapping and non-redundant functions in tumorigenesis and embryonic development , 2008, Oncogene.

[40]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[41]  L. Zon,et al.  BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma , 2005, Current Biology.

[42]  K. Knuth,et al.  What Is a Question , 2004, physics/0403089.

[43]  Sridhar Ramaswamy,et al.  Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability , 2002, Cell.

[44]  A. Look,et al.  Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[45]  F. Collins,et al.  Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines , 1993, Nature Genetics.

[46]  A. Letai,et al.  To Prime, or Not to Prime: That Is the Question. , 2016, Cold Spring Harbor symposia on quantitative biology.

[47]  Charles K Kaufman.  Zebrafish Melanoma. , 2016, Advances in experimental medicine and biology.